iBio, Inc. (IBIO) Stock Price & How to Invest

iBio, Inc. is a clinical-stage biotechnology company that applies artificial intelligence and proprietary 3D modeling of subdominant and conformational epitopes to discover antibodies that other approaches have struggled to develop. Its focus is obesity, cardiometabolic, and cardiopulmonary diseases, an area drawing intense interest as GLP-1 weight-loss drugs create demand for therapies that preserve lean muscle mass. The lead program, IBIO-600, is a long-acting anti-myostatin antibody engineered for infrequent dosing that iBio positions as potentially best-in-class; the company dosed the first participant in a Phase 1 trial in Australia in 2026, becoming a clinical-stage company. A second program, IBIO-610, is an activin E antibody that reduced visceral and total fat in obese non-human primate studies.

The investment picture in mid-2026 is defined by early science and heavy reliance on capital markets. iBio generates essentially no product revenue and, like most early-stage biotechs, funds operations by raising money through stock and warrant sales. It reported cash, equivalents, and debt securities of roughly $74.8 million as of March 31, 2026, and has said financings including a PIPE and warrant exercises extended its runway into fiscal 2028. The company has a history of reverse stock splits, including a 1-for-20 combination in late 2023, used to maintain listing requirements. With a market cap in the tens of millions of dollars, iBio sits firmly in micro-cap territory, where trading can be thin and volatile and a single trial result can move the stock dramatically.

The dominant risk is that iBio is a speculative, essentially pre-revenue micro-cap whose survival depends on continually raising money. Because it funds itself by issuing stock and warrants, ongoing dilution can erode the value of existing shares even if the science progresses, and its history of reverse stock splits (including 1-for-20 in 2023) reflects the pressure such dilution puts on the share price and on listing requirements. Cash runway is finite: if trials slow or markets close, the company could face a going-concern-type squeeze and need to raise on worse terms. Pipeline outcomes are binary and early, so a failed or ambiguous readout for IBIO-600 or IBIO-610 could sharply cut the stock. It also competes against far larger, better-funded rivals in obesity. Thin trading, high volatility, and the real possibility of a total loss make position sizing critical.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see iBio, Inc.'s investor relations page or your broker.

• Revenue: Essentially none from products; iBio is a clinical-stage biotech with only minimal reported revenue, so standard sales-based metrics do not apply
• Net loss: Consistently loss-making, as expected for a company investing in R&D ahead of any approved product; losses are funded by capital raises
• Cash position / runway: Roughly $74.8 million in cash, equivalents, and debt securities as of March 31, 2026; management has said financings extend the runway into fiscal 2028
• Market cap (micro-cap): In the tens of millions of dollars in mid-2026, placing IBIO firmly in micro-cap territory with the volatility that implies
• Shares outstanding / dilution: Grown through PIPEs and warrant exercises, with a history of reverse stock splits (including 1-for-20 in late 2023) to maintain listing requirements
• Analyst coverage: Thin; only a small number of analysts follow the stock, so published targets should be treated as low-confidence and can change quickly

Figures are approximate and tied to the asOf date; verify live numbers before acting. For a pre-revenue clinical-stage biotech, traditional valuation multiples such as P/E are not meaningful because there are no sustained earnings. What matters far more is cash runway versus burn rate, the pace and results of clinical trials, and how much dilution future funding requires. Treat any single quarter's cash figure and any analyst target as a snapshot, not a stable anchor.

There are three common ways to get IBIO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so IBIO sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where IBIO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

iBio is a speculative, clinical-stage micro-cap betting on AI-designed antibodies for obesity and cardiometabolic disease. With no product revenue, a runway funded by dilution, and value tied to binary trial readouts, it suits only risk-tolerant investors who can accept a possible total loss.